Key result
Pre-implant ECG lead 1 ratio ≥ 12 is linked to ~46% higher CRT response.
Why the study?
Despite strict patient selection using QRS duration and LBBB presence, one-third of patients have a sub-optimal response to CRT, prompting evaluation of lead one ratio as a response marker.
Does a pre-implant lead one ratio (LOR) ≥ 12 predict better clinical response and outcomes in patients receiving cardiac resynchronization therapy?
Cohort (n=93)
No
Does a pre-implant lead one ratio (LOR) ≥ 12 predict better clinical response and outcomes in patients receiving cardiac resynchronization therapy?
Answers are grounded in this paper and cite their sources.
A pre-implant lead one ratio ≥ 12 on a standard 12-lead ECG is a novel marker associated with better clinical response and lower mortality in patients undergoing cardiac resynchronization therapy.
BACKGROUND: Wider QRS duration and presence of left bundle branch block (LBBB) predict better cardiac resynchronization therapy (CRT) response. Despite strict patient selection, one-third of patients have a sub-optimal response. We aim to evaluate the impact of lead one ratio (LOR) on CRT response. METHODS: We enrolled 93 patients receiving CRT from August 2016 to August 2019. Pre-implant 12-lead electrocardiogram (ECG) was recorded, and LOR was derived by dividing the maximum positive deflection of QRS complex in ECG lead I by the maximum negative deflection in lead I; cut-off value of 12 was used to divide the cohort into two groups. Patients were followed for 6 months, and outcomes were compared for CRT response, New York Heart Association (NYHA) class improvement, all-cause mortality, and heart failure (HF) hospitalization events. RESULTS: At the end of 6-month follow-up, LOR ≥ 12 was associated with significantly better CRT response (75.76% vs. 51.85% in LOR < 12, P = 0.02), lower mortality per 100 patient-years (9.09 vs. 14.81 in LOR < 12, P = 0.012), and more improvement in HF symptoms (NYHA improvement) (78.79% vs. 55.56% in LOR < 12, P = 0.02). Patients with LOR < 12 had more HF hospitalization events (2.04 vs. 1.81 episodes in LOR ≥ 12, P = 0.029) and less QRS narrowing (∆5.74 ± 2.09 vs. ∆7.10 ± 3.97 ms in LOR ≥ 12, P = 0.01). QRS duration and LBBB morphology were predictors of response in both groups of patients. CONCLUSION: LOR ≥ 12 was associated with better response to CRT, less HF hospitalization, and more relief in HF symptoms. This ratio helps to identify possible sub-optimal response among patients with an indication for CRT.
No takes yet. Share an insight, caveat, or question.
Raj et al. (2021) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=93). Lead one ratio (LOR) ≥ 12 vs. Lead one ratio (LOR) < 12 was evaluated on Cardiac resynchronization therapy (CRT) response (≥ 5% absolute increase in LVEF and > 1 class improvement in NYHA) (p=0.02). A pre-implant electrocardiogram lead one ratio ≥ 12 was associated with a higher cardiac resynchronization therapy response rate compared to a ratio < 12.
Synapse has enriched 10 related papers. Consider them for comparative context: